The market is rewarding platforms that promise to rewrite instructions rather than merely manage symptoms. Eli Lilly and Company (LLY) is teaming up with privately held Ascidian Therapeutics in a deal valued at up to $1.9 billion, giving Lilly exclusive, target-specific rights…
Eli Lilly’s (LLY) latest vaccine shopping spree and GeoVax Labs’s (GOVX) sharpened strategic focus together seemingly sketch a quietly bullish subplot in an otherwise noisy biotech market, giving investors a fresh angle on infectious disease and immuno-oncology risk-on exposure.
Big Pharma…
Eli Lilly is turning its GLP-1 windfall into a broader oncology and radiopharma push, just as a new generation of targeted alpha therapies steps onto center stage with companies like NAYA Therapeutics — and investors are starting to notice that “weight loss”…
Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…
